Last reviewed · How we verify
D064 and D702, QD
D064 and D702, QD is a Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 3 development. Also known as: D064 and D702 Combination Therapy.
D064 and D702 are a fixed-dose combination targeting dual pathways in metabolic or inflammatory disease, though the specific molecular targets are not publicly disclosed.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | D064 and D702, QD |
|---|---|
| Also known as | D064 and D702 Combination Therapy |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed pharmacological data on D064 and D702 individually, the exact mechanism of this combination cannot be reliably described. The 'QD' (once daily) dosing suggests oral small-molecule agents. Chong Kun Dang Pharmaceutical's pipeline includes metabolic and inflammatory disease programs, but the precise targets and mechanism for this Phase 3 combination remain proprietary.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy (PHASE3)
- A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D064 and D702, QD CI brief — competitive landscape report
- D064 and D702, QD updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI
Frequently asked questions about D064 and D702, QD
What is D064 and D702, QD?
How does D064 and D702, QD work?
Who makes D064 and D702, QD?
Is D064 and D702, QD also known as anything else?
What development phase is D064 and D702, QD in?
Related
- Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
- Also known as: D064 and D702 Combination Therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing